U.S. Markets close in 2 hrs 54 mins

Tonix Pharmaceuticals Holding Corp. (TNXP)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.34+0.02 (+0.46%)
As of 1:04PM EDT. Market open.
People also watch
CERUCBIOHTBXMRNSIMNP
Interactive chart
Previous Close4.32
Open4.35
Bid4.32 x 600
Ask4.34 x 400
Day's Range4.25 - 4.35
52 Week Range0.33 - 9.40
Volume58,611
Avg. Volume1,303,740
Market Cap32.55M
Beta3.10
PE Ratio (TTM)-0.28
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Research7 days ago

    TNXP: Interim Analysis for HONOR Study Expected in 1H18

    By David Bautz, PhD NASDAQ:TNXP Financial Update On May 15, 2017, Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) announced financial results for the first quarter of 2017 and provided a business update. ...

  • Associated Press10 days ago

    Tonix reports 1Q loss

    On a per-share basis, the New York-based company said it had a loss of $1.27. The company's shares closed at $4.11. A year ago, they were trading at $26.30. _____ This story was generated by Automated ...

  • Zacks Small Cap Researchlast month

    TNXP: Potential for Only One Phase 3 Trial Needed for TNX-102 SL in PTSD

    Tonix Pharmaceuticals Holding Corp. (TNXP) is a pharmaceutical company focused on the development of products for treating disorder of the central nervous system. The company’s lead product, TNX-102 SL, is currently being developed as a treatment for posttraumatic stress disorder (PTSD). A Phase 3 clinical trial in military-related PTSD (the HONOR study) recently initiated, and we anticipate an unblinded interim analysis taking place in the first half of 2018.